Emergency use authorization based on data showing two doses of Sinovac are about 50 percent effective
WEDNESDAY, June 2, 2021 (HealthDay News) — China’s Sinovac COVID-19 vaccine has been approved for use in adults 18 years and older, the World Health Organization says.
The agency’s emergency use authorization of a second vaccine from China is based on data showing that two doses of Sinovac were about 50 percent effective in preventing symptoms of COVID-19, the Associated Press reported.
A study published in April by Brazilian scientists confirmed a previously reported efficacy rate of more than 50 percent for Sinovac, while a real-world study in Chile in April showed an efficacy rate of 67 percent.
Last month, WHO approved the COVID-19 vaccine by Sinopharm of China, and has also approved vaccines from Pfizer-BioNTech, AstraZeneca, Moderna, and Johnson & Johnson, the AP reported.
Nearly 3 in 4 Older Adults Express Interest in Vaccine to Prevent Dementia 
Updated COVID-19 Shot Beneficial for Those With Autoimmune Rheumatic Disease 
Trends Reported in Vaccination Coverage for Adolescents for 2025 
AAP Issues Recommendations for Pediatric RSV Vaccination in 2026-2027 Season 
4CMenB Vaccine Confers Modest Protection Against Gonorrhea in Teens 
AAP Releases Influenza Vaccine Recommendations for All Children 6 Months and Older 
Adverse Event Risk Not Up With Same Day COVID-19, Flu Vaccination 
